Wis. (WLAX/WEUX) – The Food and Drug Administration approves the Novavax COVID-19 vaccine for use in children ages 12 to 17. This weekend’s news comes after the company was granted an emergency use authorization in July for its two-dose vaccine to be administered to adults.

The Novavax vaccine could potentially appeal to unvaccinated people who would prefer a shot that is not based on the messenger RNA technology used by Pfizer and Moderna.